Vitalhub (TSE:VHI) Upgraded to Moderate Buy at Raymond James

Raymond James upgraded shares of Vitalhub (TSE:VHI) to a moderate buy rating in a research note published on Wednesday,Zacks.com reports.

Other analysts have also issued reports about the company. Canaccord Genuity Group raised their price target on Vitalhub from C$12.00 to C$12.50 and gave the stock a “buy” rating in a research note on Thursday, January 16th. Scotiabank set a C$14.00 price target on Vitalhub and gave the stock an “outperform” rating in a research note on Thursday, January 30th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of C$11.92.

Vitalhub Stock Up 6.0 %

Shares of TSE:VHI opened at C$10.24 on Wednesday. The company has a market capitalization of C$553.91 million, a P/E ratio of 166.55, a P/E/G ratio of 1.18 and a beta of 1.26. Vitalhub has a 52-week low of C$5.80 and a 52-week high of C$12.09. The stock’s fifty day simple moving average is C$10.48 and its 200-day simple moving average is C$10.32.

Vitalhub Company Profile

Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.